β-LAKTAM RING ANTIBIOTIC SENSITIVITY PATTERNS BACTERIA Klebsiella pneumoniae VITEK 2 COMPACT RESULTS FOR ISPA PATIENTS

Abstract

Background : Data reports on the incidence of infection cases caused by ESBL-producing Klebsiella pneumoniae bacteria at Pasar Minggu Hospital, South Jakarta are increasing every year. This shows the incidence of multidrug resistant (MDR) bacteria which must be immediately controlled by implementing wise use of antibiotics and optimal infection control prevention.

Objective:The aim of the study was to determine the comparison of antibiotic sensitivity patterns of β-lactam rings read on the Vitek 2 Compact against K. pneumoniae ESBL bacteria in patients with acute respiratory tract infections (ARI) at Pasar Minggu Hospital, and can be used by doctors as a reference for determining the right antibiotic .

Methods and Materials : This research is observational analytic with a cross-sectional design approach. Secondary data from the identification of bacteria in sputum culture of all ISPA patients at Pasar Minggu Hospital for the period January – December 2022, totaling 129 patients. Statistical analysis uses the Wilcoxon Sign Rank Test with a confidence level (CI) of 95%.

Results and Conclusions : Results of statistical analysis showed a significant difference in the sensitivity of Klebsiella pneumoniae ESBL growth between antibiotics in the ampicillin class and amoxicillin clavulanate p-value 0.000 (p <0.05). There was no significant difference in sensitivity to the growth of Klebsiella pneumoniae ESBL between the antibiotics imipenem and meropenem, p-value 0.317 (p>0.05). The best antibiotic sensitivity in inhibiting the growth of Klebsiella pneumoniae ESBL bacteria in ARI patients at Pasar Minggu Regional Hospital was in the Imipenem and Meropenem groups with sensitivity percentages of 90.7% and 91.5%. Meanwhile, Ampicilin is resistant to the growth of K. pneumonia ESBL bacteria. The results of this antibiotic sensitivity test can be used by doctors to carry out appropriate treatment for ARI patients to prevent the occurrence of antibiotic resistance and multidrug-resistance (MDR).